Skip to main content
Erschienen in: Cancer Immunology, Immunotherapy 2/2012

01.02.2012 | Original article

Interleukin 6 mediates production of interleukin 10 in metastatic melanoma

verfasst von: Mizue Terai, Masumi Eto, Garbo D. Young, David Berd, Michael J. Mastrangelo, Yutaka Tamura, Kenichi Harigaya, Takami Sato

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2012

Einloggen, um Zugang zu erhalten

Abstract

We previously reported that substantial amounts of IL-10, an immunomodulatory cytokine, are produced by cell suspensions of fresh human metastatic melanoma tissues. Production diminished with continuous culturing of cells, which suggests a pivotal interactive role between melanoma cells and the tumor microenvironment. In this study, we found that the culture media obtained from LPS-stimulated peripheral blood mononuclear cells induced IL-10 production by metastatic melanoma cells. Of the multiple cytokines present in the conditioned culture media, IL-6 was identified as the inducer of IL-10 production. A neutralizing antibody against IL-6 completely blocked the conditioned medium-induced IL-10 production. Metastatic melanoma cells that constitutively produce low amount of IL-10 increased IL-10 production in response to recombinant human IL-6 in a dose-dependent fashion. The response to exogenously added IL-6 was less significant in melanoma cells that produced high amounts of IL-6, probably due to pre-existing autocrine stimulation of IL-10 by endogenous IL-6. On the other hand, metastatic melanoma cells that do not constitutively produce IL-10 protein did not respond to exogenous IL-6. In IL-6-responsive melanoma cells, IL-6 increased STAT3 phosphorylation and inhibition of STAT3 signaling using siRNA or inhibitors for JAKs diminished IL-6-induced IL-10 production. In addition, inhibition of MEK and PI3K, but not mTOR, interfered with IL-10 production. Taken together, the data suggest that blocking of these signals leading to IL-10 production is a potential strategy to enhance an anti-melanoma immune response in metastatic melanoma.
Literatur
1.
Zurück zum Zitat Colombo MP, Mantovani A (2005) Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 65:9113–9116PubMedCrossRef Colombo MP, Mantovani A (2005) Targeting myelomonocytic cells to revert inflammation-dependent cancer promotion. Cancer Res 65:9113–9116PubMedCrossRef
2.
Zurück zum Zitat Gabrilovich DI, Chen HL, Girgis KR et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103PubMedCrossRef Gabrilovich DI, Chen HL, Girgis KR et al (1996) Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 2:1096–1103PubMedCrossRef
3.
Zurück zum Zitat Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–190PubMedCrossRef Moore KW, O’Garra A, de Waal Malefyt R, Vieira P, Mosmann TR (1993) Interleukin-10. Annu Rev Immunol 11:165–190PubMedCrossRef
4.
Zurück zum Zitat Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy—review of a new approach. Pharmacol Rev 55:241–269PubMedCrossRef Asadullah K, Sterry W, Volk HD (2003) Interleukin-10 therapy—review of a new approach. Pharmacol Rev 55:241–269PubMedCrossRef
5.
Zurück zum Zitat Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22:929–979PubMedCrossRef Pestka S, Krause CD, Sarkar D, Walter MR, Shi Y, Fisher PB (2004) Interleukin-10 and related cytokines and receptors. Annu Rev Immunol 22:929–979PubMedCrossRef
6.
Zurück zum Zitat Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D (1995) Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41:151–156PubMedCrossRef Lattime EC, Mastrangelo MJ, Bagasra O, Li W, Berd D (1995) Expression of cytokine mRNA in human melanoma tissues. Cancer Immunol Immunother 41:151–156PubMedCrossRef
7.
Zurück zum Zitat Sato T, McCue P, Masuoka K et al (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383–1390PubMed Sato T, McCue P, Masuoka K et al (1996) Interleukin 10 production by human melanoma. Clin Cancer Res 2:1383–1390PubMed
8.
Zurück zum Zitat Kim J, Modlin RL, Moy RL et al (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 155:2240–2247PubMed Kim J, Modlin RL, Moy RL et al (1995) IL-10 production in cutaneous basal and squamous cell carcinomas. A mechanism for evading the local T cell immune response. J Immunol 155:2240–2247PubMed
9.
Zurück zum Zitat Ordemann J, Jacobi CA, Braumann C, Schwenk W, Volk HD, Muller JM (2002) Immunomodulatory changes in patients with colorectal cancer. Int J Colorectal Dis 17:37–41PubMedCrossRef Ordemann J, Jacobi CA, Braumann C, Schwenk W, Volk HD, Muller JM (2002) Immunomodulatory changes in patients with colorectal cancer. Int J Colorectal Dis 17:37–41PubMedCrossRef
10.
Zurück zum Zitat Knoefel B, Nuske K, Steiner T et al (1997) Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 17:95–102PubMedCrossRef Knoefel B, Nuske K, Steiner T et al (1997) Renal cell carcinomas produce IL-6, IL-10, IL-11, and TGF-beta 1 in primary cultures and modulate T lymphocyte blast transformation. J Interferon Cytokine Res 17:95–102PubMedCrossRef
11.
Zurück zum Zitat Green AR, Green VL, White MC, Speirs V (1997) Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72:937–941PubMedCrossRef Green AR, Green VL, White MC, Speirs V (1997) Expression of cytokine messenger RNA in normal and neoplastic human breast tissue: identification of interleukin-8 as a potential regulatory factor in breast tumours. Int J Cancer 72:937–941PubMedCrossRef
12.
Zurück zum Zitat Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67–68PubMedCrossRef Dummer W, Becker JC, Schwaaf A, Leverkus M, Moll T, Brocker EB (1995) Elevated serum levels of interleukin-10 in patients with metastatic malignant melanoma. Melanoma Res 5:67–68PubMedCrossRef
13.
Zurück zum Zitat Nacinovic-Duletic A, Stifter S, Dvornik S, Skunca Z, Jonjic N (2008) Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol 30:230–239PubMedCrossRef Nacinovic-Duletic A, Stifter S, Dvornik S, Skunca Z, Jonjic N (2008) Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma. Int J Lab Hematol 30:230–239PubMedCrossRef
14.
Zurück zum Zitat Guney N, Soydinc HO, Basaran M et al (2009) Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin’s lymphoma. Asian Pac J Cancer Prev 10:669–674PubMed Guney N, Soydinc HO, Basaran M et al (2009) Serum levels of interleukin-6 and interleukin-10 in Turkish patients with aggressive non-Hodgkin’s lymphoma. Asian Pac J Cancer Prev 10:669–674PubMed
15.
Zurück zum Zitat Mapara MY, Sykes M (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22:1136–1151PubMedCrossRef Mapara MY, Sykes M (2004) Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance. J Clin Oncol 22:1136–1151PubMedCrossRef
16.
Zurück zum Zitat Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ (2004) Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22:403–415PubMedCrossRef Berd D, Sato T, Maguire HC Jr, Kairys J, Mastrangelo MJ (2004) Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J Clin Oncol 22:403–415PubMedCrossRef
17.
Zurück zum Zitat Berd D, Maguire HC Jr, Schuchter LM et al (1997) Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359–2370PubMed Berd D, Maguire HC Jr, Schuchter LM et al (1997) Autologous hapten-modified melanoma vaccine as postsurgical adjuvant treatment after resection of nodal metastases. J Clin Oncol 15:2359–2370PubMed
18.
Zurück zum Zitat Berd D, Maguire HC Jr, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572–2577PubMed Berd D, Maguire HC Jr, Mastrangelo MJ (1986) Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res 46:2572–2577PubMed
19.
Zurück zum Zitat Galizia G, Orditura M, Romano C et al (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169–178PubMedCrossRef Galizia G, Orditura M, Romano C et al (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102:169–178PubMedCrossRef
20.
Zurück zum Zitat Negrier S, Perol D, Menetrier-Caux C et al (2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6–from the Groupe Francais d’Immunotherapie. J Clin Oncol 22:2371–2378PubMedCrossRef Negrier S, Perol D, Menetrier-Caux C et al (2004) Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: prognostic value of interleukin-6–from the Groupe Francais d’Immunotherapie. J Clin Oncol 22:2371–2378PubMedCrossRef
21.
Zurück zum Zitat Porta C, De Amici M, Quaglini S et al (2008) Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 19:353–358PubMedCrossRef Porta C, De Amici M, Quaglini S et al (2008) Circulating interleukin-6 as a tumor marker for hepatocellular carcinoma. Ann Oncol 19:353–358PubMedCrossRef
22.
Zurück zum Zitat Mouawad R, Benhammouda A, Rixe O et al (1996) Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 2:1405–1409PubMed Mouawad R, Benhammouda A, Rixe O et al (1996) Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res 2:1405–1409PubMed
23.
Zurück zum Zitat Taga T, Hibi M, Hirata Y et al (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573–581PubMedCrossRef Taga T, Hibi M, Hirata Y et al (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell 58:573–581PubMedCrossRef
24.
Zurück zum Zitat Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149:2021–2027PubMed Mackiewicz A, Schooltink H, Heinrich PC, Rose-John S (1992) Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins. J Immunol 149:2021–2027PubMed
25.
Zurück zum Zitat Oh JW, Revel M, Chebath J (1996) A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Cytokine 8:401–409PubMedCrossRef Oh JW, Revel M, Chebath J (1996) A soluble interleukin 6 receptor isolated from conditioned medium of human breast cancer cells is encoded by a differentially spliced mRNA. Cytokine 8:401–409PubMedCrossRef
26.
Zurück zum Zitat Muller-Newen G, Kuster A, Hemmann U et al (1998) Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 161:6347–6355PubMed Muller-Newen G, Kuster A, Hemmann U et al (1998) Soluble IL-6 receptor potentiates the antagonistic activity of soluble gp130 on IL-6 responses. J Immunol 161:6347–6355PubMed
27.
Zurück zum Zitat Winston LA, Hunter T (1995) JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem 270:30837–30840PubMedCrossRef Winston LA, Hunter T (1995) JAK2, Ras, and Raf are required for activation of extracellular signal-regulated kinase/mitogen-activated protein kinase by growth hormone. J Biol Chem 270:30837–30840PubMedCrossRef
28.
Zurück zum Zitat Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819PubMedCrossRef Taga T, Kishimoto T (1997) Gp130 and the interleukin-6 family of cytokines. Annu Rev Immunol 15:797–819PubMedCrossRef
29.
Zurück zum Zitat Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20PubMedCrossRef Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374:1–20PubMedCrossRef
30.
Zurück zum Zitat Lucas M, Zhang X, Prasanna V, Mosser DM (2005) ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 175:469–477PubMed Lucas M, Zhang X, Prasanna V, Mosser DM (2005) ERK activation following macrophage FcgammaR ligation leads to chromatin modifications at the IL-10 locus. J Immunol 175:469–477PubMed
31.
Zurück zum Zitat Brose MS, Volpe P, Feldman M et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997–7000PubMed Brose MS, Volpe P, Feldman M et al (2002) BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 62:6997–7000PubMed
32.
Zurück zum Zitat Wan PT, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867PubMedCrossRef Wan PT, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116:855–867PubMedCrossRef
33.
Zurück zum Zitat Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR (2004) The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 24:2923–2931PubMedCrossRef Goodall J, Wellbrock C, Dexter TJ, Roberts K, Marais R, Goding CR (2004) The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol 24:2923–2931PubMedCrossRef
34.
Zurück zum Zitat Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651–1656PubMedCrossRef Sumimoto H, Imabayashi F, Iwata T, Kawakami Y (2006) The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med 203:1651–1656PubMedCrossRef
35.
Zurück zum Zitat Terai M, Tamura Y, Alexeev V et al (2009) Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother 58:1307–1317PubMedCrossRef Terai M, Tamura Y, Alexeev V et al (2009) Human interleukin 10 receptor 1/IgG1-Fc fusion proteins: immunoadhesins for human IL-10 with therapeutic potential. Cancer Immunol Immunother 58:1307–1317PubMedCrossRef
Metadaten
Titel
Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
verfasst von
Mizue Terai
Masumi Eto
Garbo D. Young
David Berd
Michael J. Mastrangelo
Yutaka Tamura
Kenichi Harigaya
Takami Sato
Publikationsdatum
01.02.2012
Verlag
Springer-Verlag
Erschienen in
Cancer Immunology, Immunotherapy / Ausgabe 2/2012
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-011-1084-5

Weitere Artikel der Ausgabe 2/2012

Cancer Immunology, Immunotherapy 2/2012 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.